Last updated August 29, 2026
Key finding
Efficacy of SR pregabalin will be assessed by visual analog scale measurements.
This study compared the efficacy and safety of pregabalin sustained-release tablets to immediate-release capsules in type 2 diabetic patients.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared the efficacy and safety of pregabalin sustained-release tablets to immediate-release capsules in type 2 diabetic patients.
Understanding the efficacy and safety of different formulations of pregabalin is crucial for optimizing treatment strategies in type 2 diabetic patients. This study's findings can guide clinicians in selecting the most appropriate medication for their patients, although the unclear effectiveness suggests further research is needed.
Unclear effectiveness across all outcomes measured. Results for quality of life and treatment satisfaction were not specified. Limited information on the population's baseline characteristics. Potential lack of generalizability due to sample size or demographics.
Published in
Publication details and source links for this paper.
Seon MK, Jun HH, Bon JK. Efficacy and Safety of Pregabalin Sustained-Release Tablets vs. Immediate-Release Capsules in Type 2 Diabetic Patients. Medicine. 2023;102(17):e33701. doi:10.1097/MD.0000000000033701
Efficacy of SR pregabalin was assessed but results were unclear.
Quality of life changes were measured, but specific results were not provided.
Treatment satisfaction and quality of sleep were evaluated, with unclear outcomes.
Drug compliance was assessed, but results were not specified.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Pregabalin 150 mg/day and Efficacy of SR pregabalin assessed by visual analog scale, Quality of life, Sleep quality, and 2 more.
This study contributes evidence to
Primary intervention
Pregabalin 150 mg/day
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
5
Evidence pairs
92
Related studies
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Core evidence
The primary outcomes reported in this study.
Pregabalin 150 mg/day → Efficacy of SR pregabalin assessed by visual analog scale
Pregabalin 150 mg/day → Efficacy of SR pregabalin assessed by visual analog scale
Pregabalin 150 mg/day → Treatment adherence
Pregabalin 150 mg/day → Treatment adherence
Pregabalin 150 mg/day → Treatment satisfaction
Pregabalin 150 mg/day → Treatment satisfaction
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Pregabalin 150 mg/day and Efficacy of SR pregabalin assessed by visual analog scale, Pregabalin 150 mg/day and Quality of Life Outcomes.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies measuring Efficacy of SR pregabalin assessed by visual analog scale
Measures Efficacy of SR pregabalin assessed by visual analog scale as a key outcome.
All studies on Pregabalin 150 mg/day
Contributes to Pregabalin 150 mg/day evidence base.
All studies measuring Quality of Life Outcomes
Measures Quality of Life Outcomes as a key outcome.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Pregabalin 150 mg/day appears to improve Efficacy of SR pregabalin assessed by visual analog scale.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Efficacy of SR pregabalin assessed by visual analog scale
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Pregabalin 150 mg/day for Quality of life.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Quality of life
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Pregabalin 150 mg/day for Sleep quality.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Sleep quality
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Pregabalin 150 mg/day for Treatment adherence.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Treatment adherence
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
